7GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
8Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
9Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
7Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis:effect on lung function, health status and sputum. Respirology, 2005,10( 1 ) :46-56.
8Koskela H, Purokivi M. Inhalation of hypertonic saline: a promising therapy in bronchiectasis. Duodecim, 2011, 127 (24) : 2653 -2659.
9Kellett F, Robert NM. Nebulised 7% hypertonic saline improveslung function and quality of life in bronchiectasis. Respir Med, 2011,105 (12) : 1831-1835.
10Gupta S, Ahmed F, Lodha R, et al. Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, Controlled trail. J Trop Pediatr, 2012,58(5) :1-7.
